AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Exploring Key Emerging Trials for MPN Patients in the UK
This chapter explores promising clinical trials for essential thrombocythemia, polycythemia vera, and myelofibrosis, including LSD1 inhibitors, calreticulin-directed treatments, hepcidin targeting, and the use of ruxolitinib for high-risk patients. It discusses combination approaches with different medications in front line and second line settings for myelofibrosis.